# HEMOQUANT DETECTION OF COLORECTAL NEOPLASIA

> **NIH NIH R01** · MAYO CLINIC ROCHESTER · 1989 · $165,402

## Abstract

Compares to traditional guaiac tests like Hemoccult, HemoQuant more
reliably measures fecal blood and more likely detects bleeding from
patients with symptomatic colorectal neoplasms.  The current study
aims to (1) assess the validity of HemoQuant in detecting
asymptomatic colorectal neoplasms and to compare this with
Hemoccult result and  (2) investigate the member of fecal specimens
per test period which optimizes test validity.  As these objectives
can most efficiently be met using a population with target lesion
prevalence, patients are studied who have previously had colorectal
cancer and their first order relatives age 50 or older.  Subjects
are identified at North Center Cancer Treatment Group (NCCTG)
centers and at the Mayo Clinic.  Study assistants at the Mayo-based
central office coordinate all subsequent operations including
patient and physician correspondence, specimen handling, and data
management.  All fecal blood assays are done at Mayo laboratories.
Over the period of study this will involve at least 75,000 patient
and physician communications, the receipt and processing of 22,000
kits each containing three fecal specimens, and the management of
32 form letters.  To accomplish this logistically complex task with
minimal error, an automated system has been developed and is fully
operational which integrates our patient data base, Laboratory
Computer System, Surgical Pathology Computer System, and the
Institutional Data Base via terminal, work processor, and
electronic data transfer.  After the first two years of funding
(which represents about one year of accrual), 21% (356/700) of the
post-resection patients originally projected for study needs have
been accrued and 18.5% (2776/15,000) of first-order relatives have
been accrued.  Compliance to study procedures has exceeded 90% in
registrants.  Early observations suggest a prevalence yield of 33
colorectal neoplasms per 1000 subjects screened.  Based on the
projected accrual size of this disease-enriched population, the
power to detect a meaningful difference in test performances is
high.  The operational objective for the remaining three years of
study is to maximize accrual efficiency using the currently
established automated management system.

## Key facts

- **NIH application ID:** 3179172
- **Project number:** 2R01CA039765-04
- **Recipient organization:** MAYO CLINIC ROCHESTER
- **SAM.gov UEI:** Y2K4F9RPRRG7
- **Principal Investigator:** DAVID A AHLQUIST
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1989
- **Award amount:** $165,402
- **Award type:** 2
- **Project period:** 1985-09-01 → 1990-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3179172

## Citation

> US National Institutes of Health, RePORTER application 3179172, HEMOQUANT DETECTION OF COLORECTAL NEOPLASIA (2R01CA039765-04). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3179172. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*